Myomo (MYO) Q1 2026 earnings review
Operating Leverage Emerges, But Volume Growth Stalls
Myomo is successfully executing a strategic pivot away from high-cost, direct-to-consumer advertising towards recurring clinical referral channels. The financial results are clear: operating expenses declined 1% year-over-year, gross margins expanded to 68.2%, and net loss narrowed to $3.0 million. However, this newfound fiscal discipline comes with a severe top-line trade-off. Revenue growth decelerated sharply to just 3% YoY, and actual device unit volume shrank 5%. The entire growth story this quarter relied on a 9% increase in average selling price (ASP), raising questions about the sustainability of the top-line trajectory.
🐂 Bull Case
The company demonstrated clear operating leverage. By holding OpEx flat (-1% YoY) while modestly growing revenue, Adjusted EBITDA loss improved 20% year-over-year to $2.3 million.
Recurring patient sources (U.S. O&P channel and MyoConnect) now account for 49% of revenue, up dramatically from 25% a year ago. Revenue from the U.S. O&P channel alone surged 79% YoY.
🐻 Bear Case
Myomo recognized revenue on only 172 units in Q1, a 5% decline from the prior year. The 3% revenue growth was driven entirely by a 9% ASP increase, which is not a sustainable long-term growth engine.
While the cost per pipeline add improved sequentially to $2,550, it remains up 11% compared to Q1 2025. Generating high-quality leads remains structurally expensive.
⚖️ Verdict: ⚪
Neutral. Management deserves credit for stopping the massive cash burn seen in mid-2025 and proving that the O&P channel can scale. However, shifting from a high-growth cash-burner to a low-growth company masking volume declines with price hikes leaves the long-term equity story in transition.
Key Themes
The Shift to Recurring Revenue Channels
Myomo's deliberate pivot from volatile social media lead generation to professional networks is bearing fruit. The MyoConnect program and the U.S. O&P channel drove 49% of Q1 revenue, accelerating from 42% in Q4 2025 and 25% in Q1 2025. This structural mix shift provides much better visibility into future revenue and relies less on expensive direct-to-consumer ad campaigns.
Volume Stagnation Masked by Price Hikes
A major red flag exists beneath the headline revenue growth: the company delivered fewer actual devices. Revenue units fell 5% YoY to 172. The only reason total revenue grew was a 9% increase in the Average Selling Price (ASP) to roughly $58,800. Management cannot continually rely on price increases to offset volume shrinkage, especially given the ongoing friction with Medicare Advantage pre-authorizations.
Operating Expense Discipline Yields Leverage
After OpEx spiked over 60% YoY in early 2025, management executed a harsh course correction. Operating expenses were actually down 1% YoY in Q1 2026 to $10.1 million. Reductions in R&D and General & Administrative overhead successfully offset targeted increases in Sales & Marketing. This reversing trend in cost growth is the primary driver behind the 20% improvement in Adjusted EBITDA.
Myomo Mobile App Replaces Hardware
In a smart product optimization, Myomo launched a mobile app to replace the physical laptop computers previously provided to every MyoPro patient. This digital shift instantly reduces the company's bill-of-materials cost by over 10% per unit, serving as a key driver for the structural gross margin expansion observed in the quarter (up 100 bps to 68.2%).
Medicare Advantage Bottleneck Persists
Friction with Medicare Advantage (MA) plans remains a structural headwind to unit growth. Myomo is attempting to combat this by running a 50-subject randomized controlled trial at the University of Utah to definitively prove clinical efficacy and force MA coverage. However, enrollment sits at just 18 subjects, suggesting relief from MA payer denials is still quarters away.
Other KPIs
Decelerating sequentially but still elevated. While this metric improved 16% from Q4 2025's $3,039 peak, it is still 11% higher than the $2,300 seen in Q1 2025. Patient acquisition remains inherently expensive in this market.
Reversing. The backlog finally showed QoQ growth (+14% from Q4 2025) after a challenging year of shrinking pipelines. Combined with a 7% sequential increase in gross pipeline adds (to 723), the top-of-funnel health is beginning to stabilize.
Guidance
Accelerating slightly. The midpoint of $10.55 million implies a sequential step-up from Q1's $10.1 million, and an approximate 9% YoY growth compared to Q2 2025 ($9.65M). Management notes strong backlog entering the quarter.
Decelerating on an annual basis. The reiterated full-year midpoint of $44.5 million represents just under 9% YoY growth over FY 2025's $40.9 million total. This confirms the company has transitioned out of the hyper-growth phase (26% YoY in FY25) into a slower, more deliberate margin-expansion phase.
Key Questions
Unit Volume Declines
Revenue units declined 5% year-over-year in Q1. Is this volume contraction solely a result of pivoting away from direct-to-consumer advertising, or are there underlying demand issues? When do you expect physical unit growth to resume?
ASP Sustainability
Q1 growth was entirely supported by a 9% increase in Average Selling Price, pushing it near $59,000. How much further pricing headroom exists with payers, and at what point does price elasticity start destroying demand?
Payer Access Timeline
You noted expanding in-network access to 158 million covered lives. How long is the lag time between signing these state/regional contracts and seeing a tangible lift in first-pass authorization rates?